Trial Information

Summary: Neoadjuvant/Adjuvant Docetaxel and Estramustine in Combination with Brachytherapy and Three-Dimensional Conformal Radiotherapy

Standard treatment for prostate cancer includes radiation therapy and hormone therapy. Radiation therapy uses high energy x-rays to damage the cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens(male hormones that make prostate tissue grow). Chemotherapy uses different medicines to stop cancer cells from dividing and growing. It is not yet known whether adding chemotherapy to hormone therapy plus radiation therapy is better than hormone therapy plus radiation therapy alone. This research study is designed to see if there is any advantage to adding chemotherapy before and after radiation therapy plus hormone therapy to treat prostate cancer.
No Compensation Provided

Patient Inclusion/Exclusion Criteria:

1. Have not received any type of treatment for prostate cancer before starting this research study.
2. Diagnosed with high risk(more likely to return after local therapy) prostate cancer by transrectal ultrasound biopsy.
High risk features include:
a) Pathology Report lists Gleason Score of 8-10(Gleason score is a number the pathologist assigns based on how aggressive it looks under the microscope,scale is 0-10. Low numbers mean cancer cells look and act more like normal prostate cells and higher numbers mean cancer cells look and act very different from normal cells.)
b) Pathology Report lists Gleason score of 7, eligible only if seminal vesicle involved with prostate cancer confirmed by transrectal ultrasound guided biopsy.
3. Must be able to walk, take care of self and spend half of waking hours out of bed.

1.Treatment of any type for prostate cancer before starting on this research study
2.Gleason score on Pathology report less than or equal to 7 without prostate cancer involvement of the seminal vesicles.
3. Prostate cancer which has spread outside the prostate gland detected by x-ray, CT scan or magnetic resonance imaging.
4. Previous history of radiation therapy to the pelvis area.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.